Genetic Mutations for Predicting Pancreatic Ductal Adenocarcinoma Susceptibility Pancreatic ductal adenocarcinoma (PDAC) is the deadliest malignancy representing about 90% of all pancreatic cancers. PDAC progresses asymptomatically until death and is refractory to most treatment methods. Surgery is the most effective treatment. Nevertheless, it is well known that only 15-20% of PDAC